Aspira director buys AWHL shares, updates warrants

Aspira Women's Health director Fraser John D filed an amended Form 4 to correct the number of shares indirectly held through Seamark Capital and the presentation of his warrant holdings as of September 17, 2025.

Rhea-AI Filing Summary

Aspira Women's Health director Fraser John D filed an amended Form 4 to correct the number of shares indirectly held through Seamark Capital and the presentation of his warrant holdings as of September 17, 2025. He bought 16,389 shares of common stock at $0.45 per share and acquired a warrant for 12,292 underlying shares with a $0.75 exercise price. Following these transactions, he directly owns 566,393 common shares and holds 287,769 shares indirectly via Seamark Capital. He also holds warrants covering 900,633 shares at a $0.35 exercise price expiring in 2031 and 68,627 shares at a $2.25 exercise price expiring in 2027, plus the new warrant for 12,292 shares expiring in 2030.

Insider Trade Summary

Net Buyer: 28,681 shares

Net Buy 5 txns

Insider Fraser John D

Role Director

Bought 28,681 shs ($7K)

Type	Security	Shares	Price	Value
Purchase	Warrant (Right to Buy)	12,292	$0.00	$0.00
Purchase	Common Stock	16,389	$0.45	$7K
holding	Warrant (Right to Buy)	--	--	--
holding	Warrant (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Warrant (Right to Buy) — 981,552 contracts for 969,260 underlying shares (Direct); Common Stock — 566,393 shares (Direct); Common Stock — 287,769 shares (Indirect, By Seamark Capital)

Footnotes (1)

1. F1. This report is being filed to correct the number of shares indirectly held by Mr. Fraser on September 17, 2025 and the presentation of the warrants held on September 17, 2025.

Key Figures

Common shares purchased: 16,389 shares at $0.45 New warrant acquired: 12,292 underlying shares, $0.75 exercise Direct common shares after transaction: 566,393 shares +4 more

7 metrics

Common shares purchased 16,389 shares at $0.45 Open-market purchase on September 17, 2025

New warrant acquired 12,292 underlying shares, $0.75 exercise Derivative purchase on September 17, 2025; expires 2030

Direct common shares after transaction 566,393 shares Direct ownership following September 17, 2025 trades

Indirect common shares 287,769 shares Indirectly held via Seamark Capital as of September 17, 2025

Large warrant position 1 900,633 shares at $0.35 Warrant expiring March 5, 2031

Large warrant position 2 68,627 shares at $2.25 Warrant expiring July 9, 2027

Net buy shares equivalent 28,681 shares Net of reported buy/sell activity in transaction summary

Key Terms

Warrant (Right to Buy), open-market purchase, indirectly held, exercise price, +1 more

5 terms

Warrant (Right to Buy) financial

"security_title: "Warrant (Right to Buy)" with underlying common stock details"

open-market purchase financial

"transaction_action: "open-market purchase" for code P transactions"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirectly held financial

"correct the number of shares indirectly held by Mr. Fraser"

exercise price financial

"conversion_or_exercise_price fields such as "0.3500" and "2.2500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4/A regulatory

"amended Form 4 ownership report context in the insider filing data"

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Form 4/A for Aspira Women's Health (AWHL) show?

The Form 4/A shows that director Fraser John D corrected prior ownership details and reported new open-market purchases. He bought 16,389 common shares at $0.45 and a warrant covering 12,292 shares with a $0.75 exercise price on September 17, 2025.

How many Aspira Women's Health (AWHL) shares does Fraser John D now hold?

After the reported transactions, he directly owns 566,393 common shares and indirectly holds 287,769 shares through Seamark Capital. These holdings reflect corrected ownership figures as of September 17, 2025, combining both direct and indirect positions disclosed in the amended filing.

What warrants related to Aspira Women's Health (AWHL) does Fraser John D hold?

He holds warrants over 900,633 shares at a $0.35 exercise price expiring in 2031, and 68,627 shares at $2.25 expiring in 2027. He also acquired a new warrant for 12,292 shares at $0.75, expiring in 2030.

Was the Aspira Women's Health (AWHL) Form 4/A mainly a correction?

Yes. A footnote states the report corrects the indirectly held share count for Fraser on September 17, 2025 and the presentation of his warrants on that date. It updates, rather than newly creating, his previously reported ownership information.

Did Fraser John D buy or sell Aspira Women's Health (AWHL) stock in this Form 4/A?

The filing reports net buying activity. He made open-market purchases of 16,389 common shares at $0.45 and acquired a warrant for 12,292 underlying shares. The transaction summary shows a total net buy of 28,681 shares equivalent.

How significant are the derivative positions reported for Aspira Women's Health (AWHL)?

The filing lists sizable warrant positions: 900,633 underlying shares at $0.35 expiring in 2031 and 68,627 shares at $2.25 expiring in 2027. Together with the new 12,292-share warrant, they represent substantial potential future share acquisitions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fraser John D

(Last) (First) (Middle)

C/O ASPIRA WOMEN'S HEALTH INC

12117 BEE CAVES RD, BLDG 3-100

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aspira Women's Health Inc. [ AWHL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
09/19/2025

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		P		16,389	A	$0.45	566,393	D
Common Stock								287,769(1)	I	By Seamark Capital

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (Right to Buy)	$0.75	09/17/2025		P		12,292		09/17/2025	09/17/2030	Common Stock, par value $0.001	12,292	$0	12,292(1)	D
Warrant (Right to Buy)	$2.25							07/09/2024	07/09/2027	Common Stock, par value $0.001	68,627		68,627	D
Warrant (Right to Buy)	$0.35							09/12/2025	03/05/2031	Common Stock, par value $0.001	900,633		900,633	D

Explanation of Responses:

1. This report is being filed to correct the number of shares indirectly held by Mr. Fraser on September 17, 2025 and the presentation of the warrants held on September 17, 2025.

	/s/ John D. Fraser	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)